Articles by Dennis
Activity
-
We zijn trots! 💙 Gisteren stond Femke van der Gaag, MBA namens ons team op het podium van de regionale voorronde van de Nationale…
We zijn trots! 💙 Gisteren stond Femke van der Gaag, MBA namens ons team op het podium van de regionale voorronde van de Nationale…
Liked by Dennis Akkaya
-
New look, same commitment! 🏰✨ We are thrilled to unveil our brand-new, unique sign at our clinic! At PT&R (Partner in Trials & Research), we…
New look, same commitment! 🏰✨ We are thrilled to unveil our brand-new, unique sign at our clinic! At PT&R (Partner in Trials & Research), we…
Liked by Dennis Akkaya
-
My last JPM post. I promise. One conversation keeps replaying. A founder building in a space with maybe 400 diagnosed patients globally asked me:…
My last JPM post. I promise. One conversation keeps replaying. A founder building in a space with maybe 400 diagnosed patients globally asked me:…
Liked by Dennis Akkaya
More activity by Dennis
-
This morning I had the pleasure of joining our locale radio MijnStreek Vandaag for De Zondagmorgen show to talk about PT&R — the work we do and the…
This morning I had the pleasure of joining our locale radio MijnStreek Vandaag for De Zondagmorgen show to talk about PT&R — the work we do and the…
Liked by Dennis Akkaya
-
Reflecting on 2025 ✨ what a year full of highlights for myTomorrows ✨ with hosting the first APAC Expanded Acces conference in Singapore to many…
Reflecting on 2025 ✨ what a year full of highlights for myTomorrows ✨ with hosting the first APAC Expanded Acces conference in Singapore to many…
Liked by Dennis Akkaya
-
Walked into a Perplexity happy hour during JPM Healthcare Week. Expected the usual AI pitch. Got something different. Met Aravind Srinivas…
Walked into a Perplexity happy hour during JPM Healthcare Week. Expected the usual AI pitch. Got something different. Met Aravind Srinivas…
Liked by Dennis Akkaya
-
Very excited to hear that new FDA guidance on scalable access to individualized medicines - crossing modalities and Centers - will be coming out very…
Very excited to hear that new FDA guidance on scalable access to individualized medicines - crossing modalities and Centers - will be coming out very…
Liked by Dennis Akkaya
-
📢 Post-Trial Access: A Growing Priority for BioPharma in Global Clinical Development As the global footprint of clinical trials continues to…
📢 Post-Trial Access: A Growing Priority for BioPharma in Global Clinical Development As the global footprint of clinical trials continues to…
Liked by Dennis Akkaya
-
Sometimes in your career, you work on something you care about so much that it’s the last thing you think about at night and the first thing you…
Sometimes in your career, you work on something you care about so much that it’s the last thing you think about at night and the first thing you…
Liked by Dennis Akkaya
-
1/23-24, come find me in Boston (or online) at the 2026 Compassionate Use & Preapproval Access conference (CUPACon26), where I’ll be reprising my…
1/23-24, come find me in Boston (or online) at the 2026 Compassionate Use & Preapproval Access conference (CUPACon26), where I’ll be reprising my…
Liked by Dennis Akkaya
-
🔍 Post-trial access sits right inbetween ethics, clinical development, and real-world patient impact. In this upcoming webinar I’m excited to share…
🔍 Post-trial access sits right inbetween ethics, clinical development, and real-world patient impact. In this upcoming webinar I’m excited to share…
Liked by Dennis Akkaya
-
A big thanks to Becky Quick for launching CNBC Cures! And a special thank you to Scott Gottlieb for focusing on the incredible hope that…
A big thanks to Becky Quick for launching CNBC Cures! And a special thank you to Scott Gottlieb for focusing on the incredible hope that…
Liked by Dennis Akkaya
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content